ESC Guidelines on chronic coronary syndromes CCS
New ESC Guidelines for the diagnostics and management of chronic coronary syndromes CCS
The new guideline recommends looking at the clinical likelihood of obstructive CAD for each individual to choose the appropriate diagnostic procedure.
Stress ECG is no longer recommended to routinely rule in or rule out CAD due to its limited reclassification potential. For patients with intermediate risk and low likelihood of CAD a cardiac CTA is recommended while for patients with higher likelihood of CAD testing for ischemia is suggested.
CADScor®System in the context of the 2019 CCS Guidelines
The CADScor®System remains a valuable aid to support the decision of ruling out stable CAD. With the potentially limited capacity of imaging methods, our technology will help ruling out low risk patients and support advancing the right patients forward to more advanced assessment.
A CAD-score value of ≤20 lowers the clinical likelihood of obstructive coronary artery disease such that no further diagnostic testing is mandated.
Sept 1 on Digital Health Stage 2 of ESC 2019 Simon Winther presented for the first time the prognostic data for the CADScor®System. In summary, a CAD-score value of ≤20 suggest a safe rule out of stable of CAD. This is the first time prognostic long-term data has been presented and the study publication is in progress.
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.